Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381394 | 1.00 | AGTR2 (0.48) | AGTR2CCR5KLK7NR1H2NR1H3 | |
| SCHEMBL1984795 | 1.00 | AGTR2 (0.48) | AGTR2CCR5KLK7NR1H2NR1H3 | |
| SCHEMBL18599553 | 0.97 | NR1H2 (0.46) | AGTR2CCR5KLK7NR1H2NR1H3 | |
| SCHEMBL18495417 | 0.93 | CCR5 (0.52) | AGTR2CCR5JAK2JAK1BCHE | |
| SCHEMBL16064467 | 0.93 | CCR5 (0.52) | AGTR2CCR5JAK2JAK1BCHE | |
| SCHEMBL6785103 | 0.87 | NR1H2 (0.47) | AGTR2NR1H2NR1H3JAK2JAK1 | |
| SCHEMBL13117075 | 0.86 | L3MBTL1 (0.51) | AGTR2BCHEMAOBL3MBTL1KDM4E | |
| SCHEMBL13102888 | 0.86 | L3MBTL1 (0.51) | AGTR2BCHEMAOBL3MBTL1KDM4E | |
| SCHEMBL993829 | 0.85 | CCR5 (0.58) | CCR5JAK2JAK1GPR119 | |
| SCHEMBL16891993 | 0.85 | NR1H2 (0.38) | CCR5NR1H2NR1H3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2012019426-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
| EP-1767536-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST MED BIOTECHNOLOGY CAMS (CN) | 2011-06-29 | — | — | EP | disclosed |
| US-7759362-B2 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | INSTITUT OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-07-20 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | XINCHANG PHARMACEUTICAL FACTORY, ZHEJIANG MEDICINE CO. LTD. (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1767536-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEREOF PREPARATION AND USAGE | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-03-28 | — | — | EP | disclosed |
| EP-0603887-B1 | Bicyclic amine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-5654318-A | 1-HALOCYCLOPROPYL-3-CARBOXY-4-OXO-7-(2,8-DIAZOBICYCLO(4.3.0)-NON-8-YL)QUINOLINES; POTENT MICROBIOCIDES; NONTOXIC; REDUCED LIPOPHILICITY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0603887-A2 | Bicyclic amine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | AGTR2 166/4885CCR5 3021/4885KLK7 4679/4885 |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | NQO2, ABCG2, DHX15 | AGTR2 2399/4885CCR5 214/4885KLK7 3082/4885 |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | AGTR2 213/4885CCR5 3848/4885KLK7 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.